Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.
AffiliationDepartment of Biochemistry, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, UK.
MetadataShow full item record
AbstractInfection by high-risk HPV (human papillomavirus) is supposed to be the primary cause of cervical cancer. The HPV E2 protein (E2) is a DNA-binding protein that regulates viral gene expression and is required for efficient viral replication. Overexpression of the E2 protein in cervical cancer cells can induce growth arrest and/or apoptotic cell death, suggesting that E2 might be useful in the treatment of this disease. In the present study, we show that VP22 (herpes simplex virus VP22 protein) can be used to deliver E2 to target cells. VP22-E2 fusion proteins induce apoptosis in transiently transfected HPV-transformed cervical carcinoma cell lines. However, VP22-E2 fusion proteins do not kill COS-7 cells, probably because these cells constitutively express the simian-virus-40 T antigen and this protein sequesters the tumour suppressor protein p53. When COS-7 cells producing VP22-E2 are seeded into cultures of HPV-transformed cells, VP22-E2 enters the non-producing cells and induces apoptosis. VP22-E2 proteins produced in bacterial cells can also enter cervical cancer cells and induce apoptosis in a dose-dependent manner. Our results suggest that local delivery of VP22-E2 fusion proteins could be used to treat cervical cancer and other HPV-associated diseases.
CitationHerpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. 2004, 40 (Pt 2):157-65 Biotechnol. Appl. Biochem.
JournalBiotechnology and Applied Biochemistry
- A cancer cell-specific inducer of apoptosis.
- Authors: Green KL, Brown C, Roeder GE, Southgate TD, Gaston K
- Issue date: 2007 Jun
- VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection.
- Authors: Sheridan PJ, Lawrie A, Crossman DC, Holt CM, Newman CM
- Issue date: 2005 Mar
- Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy.
- Authors: Green KL, Southgate TD, Mulryan K, Fairbairn LJ, Stern PL, Gaston K
- Issue date: 2006 Feb
- [Antisense targeting to human papillomavirus 18 E6/E7 affects the proliferation and apoptosis of human cervical carcinoma: an in vitro experiment with HeLa cells].
- Authors: Sima N, Kong DB, Wang W, Lu YP, Wang SX, Ma D
- Issue date: 2007 Jun 19
- Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
- Authors: Zavaglia D, Lin EH, Guidetti M, Pluquet O, Hainaut P, Favrot MC, Coll JL
- Issue date: 2005 Jul